Search results for: d842V

24 04, 2015

Blueprint Medicines Presents Preclinical Data on BLU-285

By |2019-04-08T10:13:47-04:00April 24th, 2015|D842V, News, Research|

Blueprint Medicines presented new preclinical data on its drug candidate, BLU-285, and its potential value in  treatment-resistant GIST and on novel cancer drug targets at the AACR (American Association for Cancer Research) Annual Meeting [...]

24 10, 2014

LRG patient registry: powerful tool for patients, physicians and researchers

By |2019-09-20T12:41:08-04:00October 24th, 2014|News, Patient Registry, Research, Tissue Bank|

The time it takes between the appearance of first symptoms of a rare disease and when the correct diagnosis is given, is often years if not decades instead of days or weeks like it is [...]

20 02, 2014

2013 LRG Research Team Progress Report

By |2019-09-20T15:53:19-04:00February 20th, 2014|Clinical Trials, Drug Treatment, Gleevec, News, Plasma Level Testing, Research, Side Effects, Tissue Bank|

Accomplishments—Recent Progress: 1. Using mouse models, successfully attacked GIST with antibodies, essentially telling immune system to eat the cancer cells.

11 06, 2013

How ‘Next Generation’ DNA sequencing is changing the landscape of GIST research and diagnosis

By |2019-09-20T12:32:28-04:00June 11th, 2013|News, Research|

During the past dozen years gastrointestinal stromal tumors have emerged from oncologic obscurity and reached center-stage in the development of targeted therapies for solid tumors. Tyrosine kinase inhibitors (TKIs) like imatinib, sunitinib, and more recently regorafenib, have proven effective in suppressing the growth of metastatic GIST, allowing patients to live far longer than during the previous era of ineffective chemotherapy.

1 02, 2013

Personalized medicine: is it myth or reality?

By |2019-09-20T13:17:52-04:00February 1st, 2013|Advocacy, Executive Director's Report, Mutational Testing, News|

Executive Director’s report focuses on better treatment options for GISTers For my Executive Director’s report, I usually highlight the many accomplishments of the Life Raft Group. Some of which include: Launching a GIST Day [...]

21 01, 2013

Imatinib Plasma Levels Revisited – An editorial post by Jerry Call

By |2019-04-08T09:01:29-04:00January 21st, 2013|Gleevec, News|

Since we have gotten a number of questions about Gleevec (imatinib) plasma levels and testing, I think it’s time to revisit the subject, especially for newer members. Since this is a very complex subject, this may take a few emails and a few days.

5 12, 2012

Understanding Drug Classes

By |2019-09-23T14:33:52-04:00December 5th, 2012|GIST Education, Research|

Many new cancer drugs are entering clinical practice and clinical trials. Many GIST patients are no longer responding to Gleevec or Sutent and thus are looking for clinical trials. Understanding strategies and grouping these new drugs into classes with other similar drugs may help patients understand some of their choices.

22 10, 2012

Treatments by Mutation

By |2012-12-27T23:04:55-05:00October 22nd, 2012|

In most cases, treatments for GIST do not vary by mutation type. However, there are cases where treatments can be individualized according to mutation type. This is especially true during adjuvant therapy. The Treatment by [...]

12 10, 2012

GIST Survival Statistics

By |2018-07-11T12:15:52-04:00October 12th, 2012|

One of the first questions that comes to mind for newly diagnosed cancer patients is, “Am I going to die from this, and if so, when?” Factors affecting survival for GIST include: how early [...]

Need a new search?

If you didn't find what you were looking for, try a new search!

Go to Top